RYAN WENCL: Open Payments
NPI 1740936046 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$513 in 33 payments from 6 companies in 2025. Trend: 2023 $945 · 2024 $985 · 2025 $513
Food & beverage: $513
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $215 |
| Lilly USA, LLC | 1 | $125 |
| Amgen Inc. | 3 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $51 |
| ABBVIE INC. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
Products named: REXULTI, ZEPBOUND, OTEZLA, CAPLYTA, UBRELVY, Kerendia, VRAYLAR.
Industry payments across TX — which companies pay providers there.
